<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Korean Cancer Association</publisher>
				<availability status="unknown"><p>Copyright Korean Cancer Association</p>
				</availability>
				<date type="published" when="2010">2010</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Joo</forename><forename type="middle">Hoon</forename><surname>Kim</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Sun</forename><forename type="middle">Young</forename><surname>Rha</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Chan</forename><surname>Kim</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
							<affiliation key="aff2">
								<address>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Gun</forename><forename type="middle">Min</forename><surname>Kim</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Sang</forename><forename type="middle">Hyun</forename><surname>Yoon</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Ki</forename><forename type="middle">Hyang</forename><surname>Kim</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Min</forename><forename type="middle">Jae</forename><surname>Kim</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Joong</forename><forename type="middle">Bae</forename><surname>Ahn</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Hyun</forename><forename type="middle">Cheol</forename><surname>Chung</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D</roleName><forename type="first">Jae</forename><forename type="middle">Kyung</forename><surname>Roh</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
							<affiliation key="aff2">
								<address>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>M.D.</roleName><forename type="first">Hyo</forename><forename type="middle">Song</forename><surname>Kim</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department">Yonsei Cancer Center</orgName>
								<orgName type="institution">Yonsei Cancer Research Institute</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Project for Medical Science</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Department of Internal Medicine, Yonsei University College of Medicine</orgName>
								<address>
									<addrLine>Sinchon-dong, Seodaemun-gu</addrLine>
									<postCode>120-752</postCode>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Cancer Research and Treatment</title>
						<title level="j" type="abbrev">Cancer Res Treat</title>
						<idno type="ISSN">1598-2998</idno>
						<imprint>
							<publisher>Korean Cancer Association</publisher>
							<biblScope unit="volume">42</biblScope>
							<biblScope unit="issue">4</biblScope>
							<biblScope unit="page">217</biblScope>
							<date type="published" when="2010" />
						</imprint>
					</monogr>
					<idno type="DOI">10.4143/crt.2010.42.4.217</idno>
					<idno type="PMID">21253324</idno>
					<idno type="PMCID">PMC3021741</idno>
					<note type="submission">Received April 19, 2010 Accepted May 6, 2010</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T22:17+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Neoplasms</term>
					<term>Multiple primary</term>
					<term>Stomach neoplasms</term>
				</keywords>
			</textClass>
			<abstract>
				<p>I n t r o d u c t i o n Since 2002, a population-based mass-screening program for gastric cancer was started by the Ministry of Health and Welfare in Korea, resulting in increasing numbers of patients with early gastric cancer. With the increased detection of early gastric cancer and the improvement of surgical procedure during the past three decades (1-3), gastric cancer survival has improved. Long-term follow-up for recurrence has led to an increased incidence of second primary cancers (4,5). Multiple primary cancers (MPC) in one patient has been a frequent finding in recent decades. Although the mechanism for the pathogenesis of MPC has yet to be clarified, some factors such as heredity, constitution, environment, immunology, carcinogens including viruses, radiotherapy, and chemical treatments have been implicated. Increasingly elderly patient populations and improved diagnostic techniques have also been indicated as possible causes (6). Among patients with MPC, triple cancers are known to occur in 0.5%, and quadruple or quintuple cancers in less than 0.1% of the population (7). In Western Europe and the U.S., a number of cohort studies have examined the risk of a second neoplasm after the diagnosis of a specific tumor (8-10).</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>However, there are few reports of MPC for gastric cancer. This is because gastric cancer is less frequent in Western Europe and the U.S. than it is in East Asia. In addition, multiple primary cancers of three or more sites are extremely rare conditions in patients with gastric cancer. Therefore, there is little data which reports the incidence and clinical features of this rare disease entity.</p><p>Therefore, we performed this study to evaluate the incidence of gastric cancer patients with three or more primary cancers. In addition, we also investigated clinicopathologic information of metachronous and synchronous gastric cancer patients in order to improve patient management and follow-up.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>M a t e r i a l s a n d M e t h o d s 1 Patients</head><p>Between January 1995 and December 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital, Yonsei University Health System. Among these, 113 (0.1%) patients with MPC of three or more sites were registered, and 41 (36.3%) of these had synchronous or metachronous gastric cancer. Diagnosis of gastric cancer and other MPC were pathologically confirmed in all patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Methods</head><p>We retrospectively reviewed clinicopathologic features of these 41 patients with metachronous or synchronous gastric cancer in MPC of three or more sites. The following data was collected; gender, age at initial cancer diagnosis, stage, gastric cancer histology, and survival from the time of first diagnosis of cancer. The tumor stage of the gastric cancer was determined according to Tumor-Node-Metastasis (TNM) classification (American Joint Committee on Cancer, 6th edition). Two main categories were used for histological typing: differentiated type (including papillary adenocarcinoma and well and moderately differentiated tubular adenocarcinoma) and undifferentiated type (including poorly differentiated tubular adenocarcinoma, mucinous adenocarcinoma, and signet ring cell adenocarcinoma).</p><p>The MPC was defined according to Warren and Gates's criteria <ref type="bibr" target="#b10">(11)</ref>. The definition of MPC was as follows: 1) the tumor had to have definite features of malignancy, 2) the tumor had to be separate and distinct from the index tumor, which was gastric adenocarcinoma in this study, 3) the possibility of the tumor being a metastasis of the index tumor had to be ruled out. Based on this definition, we selected a total of 113 patients with three or more primary cancers between 1995 and 2009. Then, we selected 41 patients who were diagnosed with primary gastric cancer, synchronously or metachronously.</p><p>In terms of the chronicity, we defined synchronous and metachronous cancer based on Moertel's definition. Synchronous cancers were defined as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later <ref type="bibr" target="#b11">(12)</ref>. Overall survival was defined as the time from first primary cancer diagnosis to death (of any cause).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Statistics</head><p>For statistical analysis, we used the χ 2 -test and Fisher's exact test for categorical variables and the student's t-test for continuous variables. The survival curve was calculated using the Kaplan-Meier method and the statistical difference in prognosis was analyzed using a log rank test. SPSS ver. 17.0 (SPSS Inc., Chicago, IL) was used throughout and p-values of ＜0.05 were considered significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R e s u l t s 1 Clinicopathologic features of synchronous and metachronous MPC</head><p>A total of 41 gastric cancer patients were diagnosed with three or more primary sites (GC-MPC). Among these, 34 (82.9%) had triple, 6 (14.6%) had quadruple and 1 (2.4%) had quintuple primary malignancies. Seventeen patients (41.5%) were diagnosed with MPC synchronously, whereas 24 (58.5%) were diagnosed metachronously.</p><p>Among 17 patients with synchronous GC-MPC, 6 patients were diagnosed with other malignancies before gastric cancer. In addition, 8 of 17 patients had 1 simultaneous malignancy in addition to gastric cancer, and 8 other patients had 2. Furthermore, one patient was diagnosed simultaneously with 3 other malignancies (esophagus, rectum, small bowel). Meanwhile, of 24 patients diagnosed with metachronous GC-MPC, 13 patients developed other malignancies after gastric cancer and 11 had other malignancies before gastric cancer.</p><p>Clinicopathologic data for synchronous and metachronous GC-MPC patients are described in <ref type="table">Table 1</ref>. Twenty-nine (70.7%) patients were male, and the median age was 59 years (range, 27 to 79 years). The median time interval between the first cancer and the second cancer was 42 months (range, 11.5 to 225.2 months) and the time interval between the second and third cancer was 43 months (range, 7.7 to 133.3 months). Of the 39 evaluable patients, the TNM stage of the gastric cancer was early stage (I or II) in 34 cases (82.9%) and advanced stage (III or IV) in 5 cases (12.2%).</p><p>Regarding stage, histology, and time interval between each cancer, there were no differences between the synchronous and metachronous groups. Patients in the metachronous group had more female (p=0.003) and younger (p=0.013) patients than those in synchronous group. The incidence of early-stage and poorlydifferentiated tumor was slightly higher in gastric cancer patients with metachronous GC-MPC than in those with synchronous GC-MPC (91.7% vs. 70.6% for stage I/II and 54.2% vs. 23.5% for poorly differentiated histology, respectively). Excluding gastric cancer, we also analyzed the stages of the other primary cancers. In the subset analysis, early stage cancers were slightly more frequent in the synchronous group (25% vs. 42.3%) without statistical significance (p=0.217).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Site distribution of MPC</head><p>For a total of 41 patients, the most common site of MPC other than gastric cancer was colorectal cancer (n=16, 39%), followed by cancers in the lung (n=10, 24.4%), head &amp; neck (n=10, 24.4%), and thyroid (n=9, 22%), as shown in <ref type="table" target="#tab_0">Table 2</ref> and <ref type="figure" target="#fig_1">Fig. 1A</ref>. We also analyzed site distribution of MPC according to the chronicity. Among the 17 synchronous gastric cancer patients, other common primary sites were as follows ( <ref type="figure" target="#fig_1">Fig. 1B)</ref>: head &amp; neck (n=8, 47.1%), esophagus (n=6, 35.3%) and lung (n=4, 23.5%). In contrast, the most common sites for the 24 metachronous patients were: colorectum (n=14, 58.3%), thyroid (n=7, 29.2%) and lung (n=6, 25%). By way of comparison, esophageal cancer and head &amp; neck cancer were demonstrated more frequently in the synchronous group (35.3% vs. 4.2%, p≤0.001 and 47.1% vs. 8.3%, p=0.008, respectively) while colorectal cancer was more frequent in the metachronous group (58.3% vs. 11.8%, p=0.003).</p><p>We also analyzed the site distribution of MPC in terms of gender distribution. Among 41 GC-MPC patients, 29 (70.7%) patients were male and 12 (29.3%) were female. In males, the most common site for MPC was the head &amp; neck (n=10, 34.5%), followed by the colorectum (n=9, 31%), lung (n=7, 24.1%), kidney (n=7, 24.1%), and esophagus (n=6, 20.7%) as shown in <ref type="figure" target="#fig_2">Fig. 2A</ref>. In females, the most common site was the colorectum (n=7, 58.3%), followed by the thyroid (n=4, 33.3%), breast (n=4, 33.3%), and endometrium (n=3, 25%).  <ref type="table">Table 1</ref>. Clinicopathologic data for patients with gastric cancer in multiple primary cancers of more than three sites *gastric cancer with multiple primary cancer, � this time interval indicates the onset duration between two cancers other than synchronous cancers.</p><p>When categorizing primary cancer sites based on smoking correlation, male patients demonstrated more frequent smoking related cancers such as head &amp; neck, lung, kidney, esophagus, bladder cancers than female patients (n=34, 53.1% vs. n=4, 15.4%, respectively, p=0.002). <ref type="figure" target="#fig_2">Fig. 2B</ref> and 2C compare the patients with synchronous primary cancer and those with metachronous primary cancer with regard to gender. In the metachronous group, the primary site distribution by gender was similar to that of the overall distribution <ref type="figure" target="#fig_2">(Fig. 2B)</ref>. Conversely, in the synchronous group, the majority of patients were male and the primary site distribution by gender was different from the overall distribution <ref type="figure" target="#fig_2">(Fig. 2C)</ref>. The most common sites in descending frequency were: the head &amp; neck, esophagus, lung, liver, kidney, and colorectum.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Survival outcome and cause of death</head><p>With a median follow-up duration for the whole group (41 patients) of 5.6 years (range, 0.1 to 23.2 years), the median overall survival duration and 10-year overall survival rate were 14.8 years (figure not shown) and 63.2%, respectively. The same figures for the synchronous and metachronous GC-MPC groups, respectively, were 4.7 years and 48.2%, and 14.8 years and 80.7% (p＜0.001) <ref type="figure">(Fig. 3)</ref>. We analyzed overall survival by gender, stage distribution, and gastric cancer histology. The survival differences between the synchronous and metachronous GC-MPC groups were significant in male (p=0.002), stage I/II (p=0.011) and well differentiated histology (p=0.01) groups, while the difference in female (p=0.629), stage III/IV (p=0.502) and poorly differentiated histology (p=0.154) groups did not reach statistical significance <ref type="table" target="#tab_2">(Table 3)</ref>.</p><p>At the time of the analysis, 13 patients had died of either gastric or other primary cancers. Of these 13 patients, 8 patients were metachronous and 5 patients were synchronous. The causes of death are presented in <ref type="table" target="#tab_3">Table 4</ref>.   </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>D i s c u s s i o n</head><p>We described the clinicopathologic features of a rare disease entity, GC-MPC, and analyzed its clinical significances to establish follow-up plan in cancer patients. During the 15 year investigation period, 0.1% of cancer patients had a MPC with three or more primary sites, and 36.3% of these were gastric cancer patients. This incidence is consistent with previous studies which reported prevalences of 0.029 to 1.7% <ref type="bibr" target="#b6">(7,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14)</ref>.</p><p>Synchronous and metachronous gastric cancer patients showed somewhat different second cancer distribution. For metachronous gastric cancer patients, the most common cancer sites in descending order were: colorectum, thyroid, lung, kidney and breast. This finding is similar to the distribution of cancer in the general Korean population (15): stomach, colorectum, thyroid, breast, liver and lung in descending order of frequency. However, interestingly, the site distribution for synchronous gastric cancer demonstrated a different order: head &amp; neck, esophagus, lung, and kidney. A possible reason for this phenomenon may be shared risk factors, especially cigarette smoking. Smoking is thought to be a risk factor for gastric cancer <ref type="bibr" target="#b15">(16,</ref><ref type="bibr" target="#b16">17)</ref>. The gender difference between synchronous and metachronous gastric cancer also supports this assumption. More male gastric cancer patients were diagnosed initially with multiple synchronous sites than female patients. In further subgroup analysis, smoking related cancers (head &amp; neck, lung, esophagus, kidney, bladder) were significantly more common in males than in female patients. This suggests that smoking plays an important role in the increased incidence of synchronous disease in male patients. More careful examination of these sites may therefore be needed at the time of diagnosis and during the followup period of the gastric cancer. Further epidemiologic study is warranted to clarify this point.</p><p>In addition, the metachronous gastric cancer group contained more female and younger cases. These findings seem to be caused by different peak ages between males and females. According to the Korean cancer registry (15), there are two peak incidences in females. Breast and thyroid cancers in females were most frequently diagnosed in the fourth and fifth decades, whereas other malignancies like gastric cancer were often found in the seventh decade. Conversely, most cancers in males were diagnosed in the seventh decade. Therefore, females were at greater risk of being diagnosed with a first primary cancer of breast or thyroid cancer at a younger age, and those who survived their first primary cancer were at greater risk of developing a metachronous second primary cancer thereafter.</p><p>Although there is still little data for the underlying mechanism, three main explanations have been put forward for MPC. First, with longer survival, there is a greater likelihood of attack by many carcinogens, resulting in the development of more precancerous lesions. Additionally, assuming the risk of cancer is constant, it is more likely that precancerous lesions will develop into clinically significant cancers due to accumulation of genetic changes <ref type="bibr" target="#b5">(6)</ref>. This mechanism is explained by multistep carcinogenesis over time and the molecular and environmental changes of body associated with the aging process. Second, "field carcinogenesis" may be another mechanism for MPC Metachronous MPC group 10-year survival rate: 80.7%</p><p>Synchronous MPC group 10-year survival rate: 48.2% p-value&lt;0.001 <ref type="figure">Fig. 3</ref>. Ten year overall survival difference between synchronous and metachronous gastric cancer with multiple primary cancer (GC-MPC).  pathogenesis <ref type="bibr" target="#b11">(12,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19)</ref>. This theory implies that if cells in a similar microenvironment or with similarly susceptible cell biology are exposed to the same dose of carcinogens for the same duration of time, they have a similar risk of developing into cancer <ref type="bibr" target="#b19">(20)</ref>. The association of upper aerodigestive tract cancer and lung cancer is a well studied example of the field carcinogenesis theory <ref type="bibr" target="#b20">(21,</ref><ref type="bibr" target="#b21">22)</ref>. Lastly, genetic vulnerability due to specific genetic mutations may be responsible. MLH1, MSH2, MSH6, PMS1, and PMS2 mutations in hereditary nonpolyposis colorectal cancer have been known to increase the genetic susceptibility for uterus, ovary, and stomach cancer <ref type="bibr" target="#b22">(23)</ref>.</p><p>The survival outcome in our study is consistent with previous studies <ref type="bibr" target="#b24">(24,</ref><ref type="bibr" target="#b25">25)</ref>, which suggests that metachronous patients have better prognoses than synchronous patients. In this study, the proportion of early stage (I or II) gastric cancer was 82.9%. Although recent developments in diagnosis and the introduction of mass screening programs have allowed increased detection of early gastric cancer, the proportion of early gastric cancer in this study is much higher than in the general population of Korea (50%). As patients with histories of cancer tend to undergo regular medical check-ups, this could lead to earlier diagnoses of new malignancies at curable stages <ref type="bibr" target="#b5">(6)</ref>. For these reasons, multiplicity of primary malignancies does not always imply a poor prognosis. Furthermore, metachronous status may sometimes result in a better survival outcome due to the detection of second or third primary cancer at earlier stages. Also, the better survival in the metachronous GC-MPC was maintained even when we did not include the favorable prognostic cancers such as thyroid or prostate cancer (data not shown).</p><p>Although our study had some unique findings, there were two potential limitations. First, the retrospective single center nature of our study may limit the generalization of our results. However, our analysis is based on data from the registry of the Yonsei Cancer Center, a major, 2000-bed tertiary hospital in Korea. This well organized and standardized tumor registry has records for every case of carcinoma in situ or carcinoma in our hospital since 1980. Therefore, the data from our registry can be interpreted as being broadly representative of Korea as a whole. Secondly, because of the long followup duration, some information was insufficient, and altered diagnostic and treatment strategies may have influenced the results. Therefore, further validation with nationwide data is needed, and this information might be useful in the establishment of a national diagnostic/treatment strategy for gastric cancer patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C o n c l u s i o n</head><p>We reported the clinical features of multiple primary cancer in gastric cancer patients. To our knowledge, this is the first study describing the clinical features and prognosis of three or more primary sites in gastric cancer. The early detection of additional primary malignancies will enable prompt management with curative intent. Therefore, based on our results, further genetic and epidemiologic studies are warranted to clarify understanding of the pathogenesis and improve therapeutic outcome.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>+</head><label></label><figDesc>+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 1 .</head><label>1</label><figDesc>Site distribution of gastric cancer with multiple primary cancer (GC-MPC) of whole 41 patients (A) and metachronous/synchronous distribution (B).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 2 .</head><label>2</label><figDesc>Site distribution according to gender differences (A), site distribution of metachronous multiple primary cancers (MPC) (B) and synchronous MPC (C) based on gender differences.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 2 .</head><label>2</label><figDesc>Site distribution of multiple primary cancers in patients with synchronous or metachronous gastric cancer gastric cancer with multiple primary cancer, � not significant.</figDesc><table><row><cell>Site</cell><cell cols="2">Synchronous GC-MPC* (n=17) GC-MPC (n=24) Metachronous</cell><cell>p-value</cell></row><row><cell>Colorectum</cell><cell>2 (11.8)</cell><cell>14 (58.3)</cell><cell>0.003</cell></row><row><cell>Esophagus</cell><cell>6 (35.3)</cell><cell>1 (4.2)</cell><cell>＜0.001</cell></row><row><cell>Small-bowel</cell><cell>1 (5.9)</cell><cell></cell><cell></cell></row><row><cell>Duodenum</cell><cell>2 (11.8)</cell><cell></cell><cell></cell></row><row><cell>Liver</cell><cell>3 (17.6)</cell><cell>1 (4.2)</cell><cell>NS �</cell></row><row><cell>Bile duct</cell><cell></cell><cell>3 (12.5)</cell><cell></cell></row><row><cell>Gallbladder</cell><cell></cell><cell>1 (4.2)</cell><cell></cell></row><row><cell>Ampula of vater</cell><cell>1 (5.9)</cell><cell></cell><cell></cell></row><row><cell>Lung</cell><cell>4 (23.5)</cell><cell>6 (25)</cell><cell>NS</cell></row><row><cell>Head &amp; neck</cell><cell>8 (47.1)</cell><cell>2 (8.3)</cell><cell>0.008</cell></row><row><cell>Thyroid</cell><cell>2 (11.8)</cell><cell>7 (29.2)</cell><cell>NS</cell></row><row><cell>Breast</cell><cell>1 (5.9)</cell><cell>3 (12.5)</cell><cell>NS</cell></row><row><cell>Endometrium</cell><cell></cell><cell>2 (8.3)</cell><cell></cell></row><row><cell>Ovary</cell><cell></cell><cell>1 (4.2)</cell><cell></cell></row><row><cell>Cervix</cell><cell></cell><cell>1 (4.2)</cell><cell></cell></row><row><cell>Kidney</cell><cell>3 (17.6)</cell><cell>4 (16.7)</cell><cell>NS</cell></row><row><cell>Prostate</cell><cell>2 (11.8)</cell><cell>2 (8.3)</cell><cell>NS</cell></row><row><cell>Ureter &amp; bladder</cell><cell>2 (11.8)</cell><cell>2 (8.3)</cell><cell>NS</cell></row><row><cell>Hematologic</cell><cell>1 (5.9)</cell><cell>2 (8.3)</cell><cell>NS</cell></row><row><cell>cancer</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Parentheses indicate percentages.</cell><cell></cell><cell></cell></row></table><note>*</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc>Difference</figDesc><table><row><cell></cell><cell cols="3">of 10-year survival rate between synchronous</cell></row><row><cell cols="3">and metachronous GC-MPC and subgroup analysis</cell><cell></cell></row><row><cell></cell><cell>10-year survival</cell><cell>10-year survival</cell><cell></cell></row><row><cell>Site</cell><cell>rate of synchronous</cell><cell>rate of metachronous</cell><cell>p-value</cell></row><row><cell></cell><cell cols="2">GC-MPC* (n=17) GC-MPC (n=24)</cell><cell></cell></row><row><cell>Total patients</cell><cell>48.2</cell><cell>80.7</cell><cell>&lt; 0.001</cell></row><row><cell>Male</cell><cell>28.1</cell><cell>81.8</cell><cell>0.01</cell></row><row><cell>Female</cell><cell>56</cell><cell>80.2</cell><cell>0.629</cell></row><row><cell>Stage</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Early (I or II)</cell><cell>37</cell><cell>84.2</cell><cell>0.011</cell></row><row><cell>Advanced (III or IV)</cell><cell>50</cell><cell>33.3</cell><cell>0.502</cell></row><row><cell>Differentiation</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Well</cell><cell>28.1</cell><cell>81.8</cell><cell>0.01</cell></row><row><cell>Poor</cell><cell>80.8</cell><cell>33.3</cell><cell>0.154</cell></row></table><note>Values indicate percentages. *gastric cancer with multiple primary cancer.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc>Site distribution of tumors in patients who died of either gastric or another primary cancer</figDesc><table><row><cell>Site</cell><cell>Synchronous GC-MPC* (n=17)</cell><cell>Metachronous GC-MPC (n=24)</cell></row><row><cell>Stomach</cell><cell>4 (50)</cell><cell></cell></row><row><cell>Colorectum</cell><cell></cell><cell>1 (25)</cell></row><row><cell>Liver</cell><cell>1 (12.5)</cell><cell>1 (25)</cell></row><row><cell>Bile duct</cell><cell></cell><cell>2 (50)</cell></row><row><cell>Lung</cell><cell>1 (12.5)</cell><cell></cell></row><row><cell>Head &amp; neck</cell><cell>1 (12.5)</cell><cell></cell></row><row><cell>Hematologic cancer</cell><cell>1 (12.5)</cell><cell>1 (25)</cell></row><row><cell>Total</cell><cell>8 (100)</cell><cell>5 (100)</cell></row><row><cell cols="3">Parentheses indicate percentages. *gastric cancer with multiple primary cancer.</cell></row></table><note></note></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Recent advances in surgical treatment have improved the survival of patients with gastric carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eigo</forename><surname>Otsuji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshiharu</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kiyoshi</forename><surname>Sawai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Akeo</forename><surname>Hagiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroki</forename><surname>Taniguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshio</forename><surname>Takahashi</surname></persName>
		</author>
		<idno type="DOI">10.1002/(sici)1097-0142(19980401)82:7&lt;1233::aid-cncr4&gt;3.3.co;2-c</idno>
		<idno type="PMID">9529013</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1233" to="1237" />
			<date type="published" when="1998-04-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Features of Early Gastric Cancer Detected by Modern Diagnostic Technique</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoichi</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masaki</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nobuhiro</forename><surname>Koyanagi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroya</forename><surname>Wada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Koji</forename><surname>Tsugawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mitsuhiro</forename><surname>Miyazaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yukiaki</forename><surname>Haraguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keizo</forename><surname>Sugimachi</surname></persName>
		</author>
		<idno type="DOI">10.1097/00004836-199807000-00012</idno>
		<idno type="PMID">9706772</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Gastroenterology</title>
		<title level="j" type="abbrev">Journal of Clinical Gastroenterology</title>
		<idno type="ISSN">0192-0790</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="60" to="62" />
			<date type="published" when="1998-07" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshihiko</forename><surname>Maehara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshiro</forename><surname>Okuyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sunao</forename><surname>Moriguchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroyuki</forename><surname>Orita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroki</forename><surname>Kusumoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daisuke</forename><surname>Korenaga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keizo</forename><surname>Sugimachi</surname></persName>
		</author>
		<idno type="DOI">10.1002/1097-0142(19920715)70:2&lt;392::aid-cncr2820700204&gt;3.0.co;2-p</idno>
		<idno type="PMID">1617589</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="392" to="395" />
			<date type="published" when="1992-07-15" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Second Primary Cancer after Diagnosis of Stomach Cancer in Osaka, Japan</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tomohiko</forename><surname>Hiyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aya</forename><surname>Hanai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Isaburo</forename><surname>Fujimoto</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1349-7006.1991.tb02700.x</idno>
		<idno type="PMID">1908843</idno>
		<idno type="PMCID">PMC5918547</idno>
	</analytic>
	<monogr>
		<title level="j">Japanese Journal of Cancer Research</title>
		<idno type="ISSN">0910-5050</idno>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="762" to="770" />
			<date type="published" when="1991-07" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Treatments for second malignancies after gastrectomy for stomach cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Furukawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hiratsuka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Iwanaga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Imaoka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Kabuto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Ishikawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatogastroenterology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="194" to="202" />
			<date type="published" when="1996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Multiple primary malignancies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Luciani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Balducci</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.seminoncol.2003.12.035</idno>
		<idno type="PMID">15112155</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/e96c/84645db214a1630e6fe5b1b87d6675f9c56d.pdf" />
	</analytic>
	<monogr>
		<title level="j">Seminars in Oncology</title>
		<title level="j" type="abbrev">Seminars in Oncology</title>
		<idno type="ISSN">0093-7754</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="264" to="273" />
			<date type="published" when="2004-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Quadruple cancer, including triple cancers in the head and neck region</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Németh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Czigner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Iván</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ujpál</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Barabás</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Szabó</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neoplasma</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="412" to="416" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Multiple primary cancers in urologic patients Audit of 19-year experience in Berlin and review of the literature</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">E</forename><surname>Wegner</surname></persName>
		</author>
		<idno type="DOI">10.1016/0090-4295(92)90296-9</idno>
		<idno type="PMID">1546416</idno>
		<idno type="PII">0090-4295(92)90296-9</idno>
		<idno type="ark">ark:/67375/6H6-XC8P97Z4-7</idno>
		<idno type="istexId">8599D166094458234238DEE704B6F8E3965D6FB7</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<title level="j" type="abbrev">Urology</title>
		<idno type="ISSN">0090-4295</idno>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="231" to="236" />
			<date type="published" when="1992-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note>Multiple primary cancers in urologic patients</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Subsequent primary cancers following bladder cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Salminen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Pukkala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Teppo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Pyrhönen</surname></persName>
		</author>
		<idno type="DOI">10.1016/0959-8049(94)90246-1</idno>
		<idno type="PMID">8204349</idno>
		<idno type="PII">0959-8049(94)90246-1</idno>
		<idno type="ark">ark:/67375/6H6-78WPF685-6</idno>
		<idno type="istexId">D0BEB50A2B3BE67C1A55D4C3D686128CA24B6F1A</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Cancer</title>
		<title level="j" type="abbrev">European Journal of Cancer</title>
		<idno type="ISSN">0959-8049</idno>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="303" to="307" />
			<date type="published" when="1994-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">MULTIPLE PRIMARY MALIGNANCIES IN RENAL CELL CARCINOMA</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Farhang</forename><surname>Rabbani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregory</forename><surname>Grimaldi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><surname>Russo</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0022-5347(01)62510-2</idno>
		<idno type="PMID">9751330</idno>
		<idno type="PII">S0022-5347(01)62510-2</idno>
		<idno type="ark">ark:/67375/6H6-3TNJTB8M-M</idno>
		<idno type="istexId">9E435077E8017BA55C9F39341447BD6D3885FF9D</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Urology</title>
		<title level="j" type="abbrev">The Journal of Urology</title>
		<idno type="ISSN">0022-5347</idno>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1255" to="1259" />
			<date type="published" when="1998-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Multiple primary, malignant tumors: a survey of the literature and statistical study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Warren</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Gates O</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cancer</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1358" to="414" />
			<date type="published" when="1932" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Multiple Primary Malignant Neoplasms of Multicentric Origin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charles</forename><forename type="middle">G</forename><surname>Moertel</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-3-642-87565-6_3</idno>
	</analytic>
	<monogr>
		<title level="m">Multiple Primary Malignant Neoplasms</title>
		<imprint>
			<publisher>Springer Berlin Heidelberg</publisher>
			<date type="published" when="1966" />
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="63" to="108" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Hayat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Howlader</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Reichman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">K</forename><surname>Edwards</surname></persName>
		</author>
		<idno type="DOI">10.1634/theoncologist.12-1-20</idno>
		<idno type="PMID">17227898</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/172b/47a768ee08129a62c799fa1308b27418585a.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Oncologist</title>
		<title level="j" type="abbrev">The Oncologist</title>
		<idno type="ISSN">1083-7159</idno>
		<idno type="ISSNe">1549-490X</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="20" to="37" />
			<date type="published" when="2007-01-01" />
			<publisher>Alphamed Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">MULTIPLE PRIMARY MALIGNANT TUMORS*</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">I</forename><surname>Hajdu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eva</forename><forename type="middle">O</forename><surname>Hajdu</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1532-5415.1968.tb03965.x</idno>
		<idno type="PMID">5634468</idno>
		<idno type="ark">ark:/67375/WNG-ZX1K7NDB-F</idno>
		<idno type="istexId">9907494CFEB5D5A86D68414968EDEF78A9CA904C</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American Geriatrics Society</title>
		<idno type="ISSN">0002-8614</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="16" to="26" />
			<date type="published" when="1968-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Annual report of Korea Central Cancer Registry. Goyang: National Cancer Center</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>National Cancer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Center</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Epidemiology of gastric cancer in Japan</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Tsugane</surname></persName>
		</author>
		<idno type="DOI">10.1136/pgmj.2004.029330</idno>
		<idno type="PMID">15998815</idno>
		<idno type="PMCID">PMC1743301</idno>
		<idno type="ark">ark:/67375/NVC-3716BJJT-V</idno>
		<idno type="istexId">7CE698CEC48713C8A4691F19783F2DFB6C61B938</idno>
		<ptr type="open-access" target="https://pmj.bmj.com/content/81/957/419.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Postgraduate Medical Journal</title>
		<title level="j" type="abbrev">Postgraduate Medical Journal</title>
		<idno type="ISSN">0032-5473</idno>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">957</biblScope>
			<biblScope unit="page" from="419" to="424" />
			<date type="published" when="2005-07-01" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cigarette Smoking and Mortality due to Stomach Cancer: Findings from the JACC Study.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshihisa</forename><surname>Fujino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tetsuya</forename><surname>Mizoue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noritaka</forename><surname>Tokui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shogo</forename><surname>Kikuchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshihiro</forename><surname>Hoshiyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideaki</forename><surname>Toyoshima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Yatsuya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kiyomi</forename><surname>Sakata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Akiko</forename><surname>Tamakoshi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Reiko</forename><surname>Ide</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tatsuhiko</forename><surname>Kubo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takesumi</forename><surname>Yoshimura</surname></persName>
		</author>
		<idno type="DOI">10.2188/jea.15.s113</idno>
		<idno type="PMID">16127222</idno>
		<ptr type="open-access" target="https://www.jstage.jst.go.jp/article/jea/15/Supplement_II/15_Supplement_II_S113/_pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Epidemiology</title>
		<title level="j" type="abbrev">Journal of Epidemiology</title>
		<idno type="ISSN">0917-5040</idno>
		<idno type="ISSNe">1349-9092</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">Supplement_II</biblScope>
			<biblScope unit="page" from="S113" to="S119" />
			<date type="published" when="2005" />
			<publisher>Japan Epidemiological Association</publisher>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Molecular epidemiology, biomarkers and cancer prevention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">Helena</forename><surname>Furberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><forename type="middle">B</forename><surname>Ambrosone</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1471-4914(01)02162-1</idno>
		<idno type="PMID">11689338</idno>
		<idno type="PII">S1471-4914(01)02162-1</idno>
		<idno type="ark">ark:/67375/6H6-TF14Z592-9</idno>
		<idno type="istexId">D3544F5A3BA625061602ACE40E63EE08EB950867</idno>
	</analytic>
	<monogr>
		<title level="j">Trends in Molecular Medicine</title>
		<title level="j" type="abbrev">Trends in Molecular Medicine</title>
		<idno type="ISSN">1471-4914</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="517" to="521" />
			<date type="published" when="2001-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">DNA methylation and cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">A</forename><surname>Jones</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.onc.1205597</idno>
		<idno type="PMID">12154398</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/1205597.pdf" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<title level="j" type="abbrev">Oncogene</title>
		<idno type="ISSN">0950-9232</idno>
		<idno type="ISSNe">1476-5594</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">35</biblScope>
			<biblScope unit="page" from="5358" to="5360" />
			<date type="published" when="2002-08" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">“Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Danely</forename><forename type="middle">P</forename><surname>Slaughter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harry</forename><forename type="middle">W</forename><surname>Southwick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Walter</forename><surname>Smejkal</surname></persName>
		</author>
		<idno type="DOI">10.1002/1097-0142(195309)6:5&lt;963::aid-cncr2820060515&gt;3.0.co;2-q</idno>
		<idno type="PMID">13094644</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="963" to="968" />
			<date type="published" when="1953-09" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Methodology for Evaluating the Incidence of Second Primary Cancers with Application to Smoking-relted Cancers from the Surveillance, Epidmiology, and End Results (SEER) Program</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colin</forename><forename type="middle">B</forename><surname>Begg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zuo-Feng</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ming</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harry</forename><forename type="middle">W</forename><surname>Herr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stimson</forename><forename type="middle">P</forename><surname>Schantz</surname></persName>
		</author>
		<idno type="DOI">10.1093/oxfordjournals.aje.a117689</idno>
		<idno type="PMID">7653476</idno>
		<idno type="ark">ark:/67375/HXZ-64NJDZ7W-H</idno>
		<idno type="istexId">583966E9BC31627C32514A6329429E3A2D989E45</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Epidemiology</title>
		<idno type="ISSN">0002-9262</idno>
		<idno type="ISSNe">1476-6256</idno>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="653" to="665" />
			<date type="published" when="1995-09-15" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Second primary cancers in patients with lung carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fabio</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lalao</forename><surname>Randimbison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Van-Cong</forename><surname>Te</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carlo</forename><surname>La Vecchia</surname></persName>
		</author>
		<idno type="DOI">10.1002/(sici)1097-0142(19990701)86:1&lt;186::aid-cncr25&gt;3.0.co;2-3</idno>
		<idno type="PMID">10391579</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="186" to="190" />
			<date type="published" when="1999-07-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Identification and Classification of Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome): Adapting Old Concepts to Recent Advancements. Report from the Italian Association for the Study of Hereditary Colorectal Tumors Consensus Group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maurizio</forename><surname>Ponz De Leon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lucio</forename><surname>Bertario</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maurizio</forename><surname>Genuardi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovanni</forename><surname>Lanza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cristina</forename><surname>Oliani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guglielmina</forename><forename type="middle">Nadia</forename><surname>Ranzani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovanni</forename><forename type="middle">Battista</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Liliana</forename><surname>Varesco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tiziana</forename><surname>Venesio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alessandra</forename><surname>Viel</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10350-007-9071-9</idno>
		<idno type="PMID">17899274</idno>
	</analytic>
	<monogr>
		<title level="j">Diseases of the Colon &amp; Rectum</title>
		<title level="j" type="abbrev">Diseases of the Colon &amp; Rectum</title>
		<idno type="ISSN">0012-3706</idno>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2126" to="2134" />
			<date type="published" when="2007-12" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
	<note type="report_type">Report</note>
	<note>from the Italian Association for the study of Hereditary Colorectal Tumors Consensus Group. Dis Colon</note>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Rectum</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007" />
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="2126" to="2160" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Synchronous and metachronous cancer of the stomach</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Marrano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Viti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Grigioni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Marra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="493" to="501" />
			<date type="published" when="1987" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Gastric adenocarcinoma in the gastric stump after partial gastrectomy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Moreaux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Mathey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Msika</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatogastroenterology</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="517" to="538" />
			<date type="published" when="1991" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
